Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
VERU Veru $1.85 -0.105 (-5.38%) 08:15 09/12/18 09/12 08:15 09/12/18 08:15 Hot Stocks	Veru announces pre-IND meeting for VERU with FDA » Veru announced that it… Veru announced that it has completed a pre-investigational new drug application, or pre-IND, meeting for VERU-111 in which the FDA agreed with Veru's plans for a Phase 1/2 clinical trial and that an IND may be submitted for the indication of men who have metastatic castration resistant prostate cancer and who have also become resistant to, or who have failed to respond to, Zytiga or Xtandi. VERU-111 is a novel, oral anti-tubulin therapy that targets alpha and beta tubulin subunits of microtubules. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ACRX AcelRx $3.23 -0.05 (-1.53%) , KURA Kura Oncology $19.95 -0.75 (-3.62%) … 07:54 09/06/18 09/06 07:54 09/06/18 07:54 Conference/Events	H.C. Wainwright to hold a conference » Rodman & Renshaw 20th… Rodman & Renshaw 20th Annual Global Investment Conference will be held in New York on September 5-6 with webcasted company presentations to begin on September 6 at 8:45 am; not all company presentations may be webcasted. Webcast Link ACRX AcelRx $3.23 -0.05 (-1.53%) KURA Kura Oncology $19.95 -0.75 (-3.62%) SYN Synthetic Biologics $2.72 -0.02 (-0.73%) TOCA Tocagen $11.15 0.18 (1.64%) SBOT Stellar Biotechnologies $1.58 0.17 (12.06%) INNV Innovus Pharmaceuticals $0.00 (0.00%) VERU Veru $1.94 0.07 (3.74%) OPGN OpGen $1.93 0.02 (1.05%) ONCS OncoSec $1.56 -0.01 (-0.64%) KOOL Cesca Therapeutics $0.45 -0.0196 (-4.21%) SRTS Sensus Healthcare $7.39 0.1 (1.37%) DARE Dare Bioscience $1.13 0.04 (3.67%) EVFM Evofem $3.93 -0.16 (-3.91%) ATRS Antares Pharma $3.48 -0.02 (-0.57%) AVGR Avinger $1.63 0.02 (1.24%) MATN Mateon Therapeutics $0.00 (0.00%) CUR Neuralstem $1.18 -0.06 (-4.84%) IDXG Interpace Diagnostics $1.53 0.03 (2.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Sep 27 Sep 29 Sep
VERU Veru $1.96 (0.00%) 08:16 08/29/18 08/29 08:16 08/29/18 08:16 Hot Stocks	Veru announces additional information regarding female condom tender award » Veru announced additional… Veru announced additional information regarding its recent award of 75% of a 120M-unit South Africa female condom tender. "The anticipated total revenue of the South Africa tender awarded to Veru is $31 million with the first-year revenue expected to be $10.4 million with up to another $10.4 million of revenue for each of years two and three," said Mitchell Steiner, chairman, president and CEO. "The revenue and positive operating margin from this tender award will help fund development of Veru's drug pipeline to make us a leading oncology and urology biopharmaceutical company. We are proud of our team for receiving this significant tender award." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VERU Veru $1.96 -0.085 (-4.16%) 08:05 08/28/18 08/28 08:05 08/28/18 08:05 Hot Stocks	Veru sees total revenue from South Africa tender award of $31M » Veru announced additional… Veru announced additional information regarding its recent award of 75% of a 120M-unit South Africa female condom tender, with CEO Mitchell Steiner stating: "The anticipated total revenue of the South Africa tender awarded to Veru is $31M with the first-year revenue expected to be $10.4M with up to another $10.4M of revenue for each of years two and three. The revenue and positive operating margin from this tender award will help fund development of Veru's drug pipeline to make us a leading oncology and urology biopharmaceutical company. We are proud of our team for receiving this significant tender award." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VERU Veru $1.96 -0.085 (-4.16%) 07:18 08/28/18 08/28 07:18 08/28/18 07:18 Recommendations	Veru analyst commentary at H.C. Wainwright » Veru female condom order… Veru female condom order could be worth $15M, says H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju believes Veru's 75% award of a South Africa female condom tender, which is in line with management's prior expectation, could be worth $15M and be delivered by the end of calendar year 2018. The tender award should provide "solid" cash flows to the company to help the continued development of its oncology and urology drug candidates, Selvaraju tells investors in a research note. He notes Veru may also receive part of the 35M unit tender from Brazil in the coming quarters. The analyst reiterates a Buy rating on the shares with a $5 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

VERU Veru Inc. $2.05 -0.055 (-2.62%) 08:10 08/27/18 08/27 08:10 08/27/18 08:10 Hot Stocks	Veru Inc. awarded 75% of a South Africa female condom tender » Veru Inc. announced that… Veru Inc. announced that its global public sector division, The Female Health Company, has been awarded 75% of a South Africa female condom tender. The overall tender is for up to 120M female condoms in total and orders may be placed under the award during the next three years. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
VERU Veru $2.06 -0.1 (-4.63%) 06:40 08/14/18 08/14 06:40 08/14/18 06:40 Earnings	Veru reports Q3 EPS (15c), consensus (8c) » Reports Q3 revenue $5.5M,… Reports Q3 revenue $5.5M, consensus $4.37M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	14 Aug
VERU Veru $2.03 0.09 (4.64%) , VRAY ViewRay $7.65 0.53 (7.44%) … 10:10 07/03/18 07/03 10:10 07/03/18 10:10 Initiation	On The Fly: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Veru Inc. (VERU) initiated with a Buy at Maxim. 2. ViewRay (VRAY) initiated with a Buy at Jefferies. 3. MeiraGTx (MGTX) initiated with an Overweight at Barclays. 4. Zafgen (ZFGN) initiated with an Overweight at Piper Jaffray. 5. Eloxx Pharmaceuticals (ELOX) initiated with a Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. VERU Veru $2.03 0.09 (4.64%) VRAY ViewRay $7.65 0.53 (7.44%) MGTX MeiraGTx $12.45 0.99 (8.64%) ZFGN Zafgen $9.77 0.23 (2.41%) ELOX Eloxx Pharmaceuticals $17.80 1.27 (7.68%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
VERU Veru $1.94 -0.08 (-3.96%) 07:50 07/03/18 07/03 07:50 07/03/18 07:50 Initiation	Veru initiated at Maxim » Veru Inc. initiated with… Veru Inc. initiated with a Buy at Maxim. Maxim analyst Jason McCarthy initiated Veru Inc. with a Buy rating and $10.00 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a quarter ago
VERU Veru $1.97 (0.00%) 08:41 06/12/18 06/12 08:41 06/12/18 08:41 Hot Stocks	Veru Inc. to initiate VERU-944 Phase 2 trial » Veru Inc. announced the… Veru Inc. announced the submission of an Investigational New Drug, or IND, application with the FDA for VERU-944. Based on previous input by the FDA, filing the IND will allow the company to advance its proprietary drug candidate, VERU-944, directly to a Phase 2 clinical study. The Phase 2 clinical study will evaluate the efficacy and safety of VERU-944 for the treatment of hot flashes caused by androgen deprivation hormone therapy in men with advanced prostate cancer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

On The Fly

News and insights, exclusive to thefly.com

10:25	JD.com drops as new WeChat messages emerge following CEO's rape accusations»
10:22	Comcast slides after topping Disney in bid to buy Sky»
10:21	On The Fly: Top five analyst initiations»
10:21	On The Fly: Top five analyst downgrades»
10:21	On The Fly: Top five analyst upgrades»

View all On The Fly Stories »

Upcoming
Events (10)

Today	ARCE	Arco Platform - ARCE
Today	UROV	Urovant Sciences - UROV
Today	SCPH	Type A Post-Action Meeting
Today		19th World Conference on Lung Cancer
Today		MedTech Conference
Today	CYDY ...	4th Annual Robins Equity Research Roundup
Today		Asia Rising Dragons 1:1 Forum
Today	MSFT ...	Microsoft Ignite
Today	APA ...	2018 Johnson Rice Energy Conference
Today	RBC ...	Gold Forum / XPL-DEV 2018

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals for your search.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial